Literature DB >> 19680625

The insulin glargine dilemma: an opportunity for the diabetes community?

M Stumvoll1, P P Nawroth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19680625     DOI： 10.1007/s00125-009-1490-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  10 in total

1.  Does diabetes therapy influence the risk of cancer?

Authors:  U Smith; E A M Gale
Journal:  Diabetologia       Date:  2009-09       Impact factor: 10.122

2.  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.

Authors:  P Kurtzhals; L Schäffer; A Sørensen; C Kristensen; I Jonassen; C Schmid; T Trüb
Journal:  Diabetes       Date:  2000-06       Impact factor: 9.461

3.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.

Authors:  L G Hemkens; U Grouven; R Bender; C Günster; S Gutschmidt; G W Selke; P T Sawicki
Journal:  Diabetologia       Date:  2009-06-30       Impact factor: 10.122

4.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.

Authors:  C J Currie; C D Poole; E A M Gale
Journal:  Diabetologia       Date:  2009-07-02       Impact factor: 10.122

5.  Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.

Authors:  J M Jonasson; R Ljung; M Talbäck; B Haglund; S Gudbjörnsdòttir; G Steineck
Journal:  Diabetologia       Date:  2009-07-09       Impact factor: 10.122

6.  Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine.

Authors:  Saskia Erbel; Christina Reers; Volker W Eckstein; Jörg Kleeff; Markus W Büchler; Peter P Nawroth; Robert A Ritzel
Journal:  Diabetes Care       Date:  2008-03-03       Impact factor: 19.112

7.  Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).

Authors:  Hertzel Gerstein; Salim Yusuf; Matthew C Riddle; Lars Ryden; Jackie Bosch
Journal:  Am Heart J       Date:  2007-11-26       Impact factor: 4.749

8.  Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.

Authors:  H M Colhoun
Journal:  Diabetologia       Date:  2009-07-15       Impact factor: 10.122

9.  Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.

Authors:  J Rosenstock; V Fonseca; J B McGill; M Riddle; J P Hallé; I Hramiak; P Johnston; M Davis
Journal:  Diabetologia       Date:  2009-07-16       Impact factor: 10.122

10.  Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.

Authors:  J Rosenstock; V Fonseca; J B McGill; M Riddle; J-P Hallé; I Hramiak; P Johnston; M Davis
Journal:  Diabetologia       Date:  2009-06-13       Impact factor: 10.122
  10 in total
  1 in total

1.  Insulin glargine and insulin have identical effects on proliferation and phosphatidylinositol 3-kinase/AKT signalling in rat thyrocytes and human follicular thyroid cancer cells.

Authors:  K Müller; C Weidinger; D Führer
Journal:  Diabetologia       Date:  2010-02-24       Impact factor: 10.122
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.